Sponsor study identifier
observational
226
1 country
1
Study Start
May 2, 2024
Actual (reported)Primary Completion
December 31, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)Background YKL-40 is a glycoprotein that had been reported to be associated with inflammation atherosclerosis and endothelial dysfunction. The objective is to explore the association of serum YKL-40 levels with nutrition status, inflammation, and body composition in a cohort of hemodialysis patients Methods We plan to recruit 400 prevalent HD patients. Their baseline serum YKL-40 levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, and nutritional indices will be measured.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2024
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 4, 2024
Actual (reported)January 16, 2024
Actual (reported)May 2, 2024
Actual (reported)December 31, 2024
Actual (reported)December 31, 2024
Actual (reported)Analysis of biomarkers of YKL40
YKL40 is also reportedly useful as an inflammation marker in HD patients
1 years
Evaluation of nutritional status and body composition
Malnutrition, with a prevalence between 40% and 75% in maintenance hemodialysis patients is the most important risk factor for morbidity, the quality of life, all-cause mortality and cardiovascular mortality.
1 years
Analysis of biomarkers of IL-6
1 years
vaspin
1 years
insulin
1 years
adiponectin
1 years
total antioxidant capacity
1 years
patients have to be at least 20-years-old and hemodialysis (HD) for at least 3 months.
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan
serum
Paik Seong Lim, PhD
Tungs' Taichung Metroharbour Hospital
226 participants (actual enrollment reported by the registry).
First Submitted
January 4, 2024
First Posted
January 16, 2024
Study Start
May 2, 2024
Actual (reported)Nutritional Supplementation in Head and Neck Cancers
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2024
Actual (reported)Study Completion
December 31, 2024
Actual (reported)Last Updated
June 6, 2025
Record last verified: 2025-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: